May. 6 at 2:16 AM
$OTLC On May 1, 2026, Oncotelic Therapeutics completed a merger in which its affiliate Holdings was merged into Merger Sub, making Merger Sub a wholly owned subsidiary of Lunai, and in exchange Oncotelic received five shares of Lunai’s Series B preferred stock with an aggregate stated value of
$12.5 million and a broad, perpetual license to exploit the transferred intellectual property outside the biodefense and Alzheimer’s disease fields. The transaction, which involved no cash consideration, strengthens Oncotelic’s strategic access to key intellectual property while, under a related asset transfer agreement, the company also agreed to issue Autotelic, Inc. common stock equal to 10% of Oncotelic’s fully diluted shares upon a future uplisting to a major U.S. exchange, potentially reshaping its capital structure and ownership profile.
